PriceTargets.com logo

Smith & Nephew SNATS - SNN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $35.75
  • Forecasted Upside: 9.29%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$32.71 As of 12/4/2025 04:59 PM ET
▼ -0.25 (-0.76%)

This chart shows the closing price for SNN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Smith & Nephew SNATS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNN

Analyst Price Target is $35.75
▲ +9.29% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Smith & Nephew SNATS in the last 3 months. The average price target is $35.75, with a high forecast of $37.50 and a low forecast of $34.00. The average price target represents a 9.29% upside from the last price of $32.71.

This chart shows the closing price for SNN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Smith & Nephew SNATS. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/17/2025Kepler Capital MarketsUpgradeStrong-Buy
11/11/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$36.00 ➝ $34.00
10/20/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform
10/14/2025Sanford C. BernsteinSet TargetOutperform ➝ Market Perform$37.50
10/14/2025Sanford C. BernsteinReiterated RatingOutperform ➝ Market Perform$37.50
10/8/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
9/27/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
8/18/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$28.00 ➝ $36.00
5/1/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$27.00 ➝ $28.00
4/25/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
4/25/2025HSBCDowngradeBuy ➝ Hold
3/17/2025Canaccord Genuity GroupReiterated RatingHold ➝ Hold$27.00 ➝ $27.00
3/12/2025UBS GroupDowngradeBuy ➝ Neutral
2/26/2025Canaccord Genuity GroupReiterated RatingHold ➝ Hold$27.00 ➝ $27.00
11/6/2024Berenberg BankDowngradeBuy ➝ Hold
11/1/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
7/24/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy
6/5/2024UBS GroupUpgradeNeutral ➝ Buy
11/28/2023BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/31/2023HSBCUpgradeHold ➝ Buy
10/13/2023Stifel NicolausInitiated CoverageHold
8/8/2023UBS GroupUpgradeSell ➝ Neutral
4/27/2023HSBCDowngradeBuy ➝ Hold
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/29/2023BarclaysDowngradeOverweight ➝ Underweight
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
3/1/2023Liberum CapitalUpgradeHold ➝ Buy
2/22/2023UBS GroupBoost TargetGBX 970 ➝ GBX 1,000
2/22/2023BarclaysLower TargetGBX 1,500 ➝ GBX 1,480
2/16/2023Liberum CapitalInitiated CoverageHold
12/12/2022CitigroupInitiated CoverageBuy
11/28/2022UBS GroupDowngradeNeutral ➝ Sell
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
10/4/2022BarclaysLower TargetGBX 1,550 ➝ GBX 1,530
8/16/2022UBS GroupLower TargetGBX 1,190 ➝ GBX 1,116
7/28/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold
7/5/2022BarclaysLower TargetGBX 1,650 ➝ GBX 1,630
5/31/2022BarclaysLower TargetGBX 1,680 ➝ GBX 1,650
4/29/2022UBS GroupBoost TargetGBX 1,200 ➝ GBX 1,295
3/15/2022Royal Bank Of CanadaInitiated CoverageOutperform
3/4/2022Redburn PartnersUpgradeSell ➝ Neutral
3/2/2022JPMorgan Chase & Co.Boost TargetGBX 1,376 ➝ GBX 1,442
11/5/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/4/2021Berenberg BankReiterated RatingBuy
9/30/2021BarclaysReiterated RatingOverweight
9/10/2021BarclaysReiterated RatingOverweight
8/17/2021Morgan StanleyReiterated RatingOverweight
8/2/2021JPMorgan Chase & Co.Reiterated RatingNeutral
7/1/2021BarclaysReiterated RatingOverweight
6/9/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
5/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral
5/4/2021Berenberg BankReiterated RatingBuy
5/4/2021Credit Suisse GroupReiterated RatingNeutral
4/30/2021BarclaysReiterated RatingOverweight
3/31/2021BarclaysReiterated RatingOverweight
2/23/2021Berenberg BankReiterated RatingBuy
2/22/2021JPMorgan Chase & Co.Reiterated RatingNeutral
2/22/2021Credit Suisse GroupReiterated RatingNeutral
2/22/2021CommerzbankDowngradeBuy ➝ Hold
1/22/2021JPMorgan Chase & Co.Reiterated RatingNeutral
1/21/2021BarclaysReiterated RatingOverweight
1/20/2021Berenberg BankReiterated RatingBuy
12/18/2020JPMorgan Chase & Co.Reiterated RatingNeutral
12/18/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$46.50
12/9/2020Morgan StanleyReiterated RatingOverweight
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.24 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 22 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 11 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 23 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 15 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 15 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Smith & Nephew SNATS logo
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: $32.71
Low: $32.68
High: $33.12

50 Day Range

MA: $34.79
Low: $32.00
High: $37.12

52 Week Range

Now: $32.71
Low: $23.69
High: $38.79

Volume

293,132 shs

Average Volume

512,482 shs

Market Capitalization

$13.88 billion

P/E Ratio

N/A

Dividend Yield

1.73%

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew SNATS?

The following Wall Street sell-side analysts have issued stock ratings on Smith & Nephew SNATS in the last twelve months: Canaccord Genuity Group Inc., Hsbc Global Res, HSBC Holdings plc, Kepler Capital Markets, Royal Bank Of Canada, Sanford C. Bernstein, UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for SNN.

What is the current price target for Smith & Nephew SNATS?

0 Wall Street analysts have set twelve-month price targets for Smith & Nephew SNATS in the last year. Their average twelve-month price target is $35.75, suggesting a possible upside of 9.3%. Sanford C. Bernstein has the highest price target set, predicting SNN will reach $37.50 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $34.00 for Smith & Nephew SNATS in the next year.
View the latest price targets for SNN.

What is the current consensus analyst rating for Smith & Nephew SNATS?

Smith & Nephew SNATS currently has 6 hold ratings, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SNN, but not buy more shares or sell existing shares.
View the latest ratings for SNN.

What other companies compete with Smith & Nephew SNATS?

Other companies that are similar to Smith & Nephew SNATS include GE HealthCare Technologies, Koninklijke Philips, Zimmer Biomet, Solventum and Penumbra. Learn More about companies similar to Smith & Nephew SNATS.

How do I contact Smith & Nephew SNATS's investor relations team?

Smith & Nephew SNATS's physical mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider's listed phone number is 441923477100 and its investor relations email address is [email protected]. The official website for Smith & Nephew SNATS is www.smith-nephew.com. Learn More about contacing Smith & Nephew SNATS investor relations.